Additional Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    University Of Alberta Hospital ( Site 4702)
    Edmonton AB. T6G 1W9
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    UCLA School of Medicine ( Site 4006)
    Los Angeles CA. 90095-1670
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    Yale University ( Site 4017)
    New Haven CT. 06519
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    Mayo Clinic - Scottsdale ( Site 4014)
    Phoenix AZ. 85054
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    Mount Sinai Hospital [Toronto, Canada] ( Site 4700)
    Toronto ON. M5T 3L9
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    Hospital For Special Surgery ( Site 4020)
    New York NY. 10021
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    Johns Hopkins Asthma and Allergy Center [Baltimore, MD] ( Site 4018)
    Baltimore MD. 21224
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    Froedtert and Medical College of Wisconsin ( Site 4012)
    Milwaukee WI. 53226
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    Pacific Arthritis Care Center ( Site 4008)
    Los Angeles CA. 90045
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    Massachusetts General Hospital ( Site 4003)
    Boston MA. 02114
    View Details

  • Xenon MRI and Progressive ILD

    Duke University
    Durham NC. 27710
    View Details

  • Bio-Banking of Specimens for Advanced Lung Disease and Lung Transplant Research

    Baylor Scott & White Research Institute
    Dallas TX. 75246
    View Details

  • The Genetics of Pulmonary Fibrosis

    University of Colorado Anschutz Medical Campus
    Aurora CO. 80045
    View Details

  • Mechanisms of Familial Pulmonary Fibrosis

    Vanderbilt University Medical Center
    Nashville TN. 37232
    View Details

  • Explanted Lung Tissues With Pulmonary Fibrosis

    The University of Chicago
    Chicago IL. 60637
    View Details

  • Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)

    Mayo Clinic
    Rochester MN. 55905
    View Details

  • Identification of Novel Markers of Human Lung Disease

    Davis Heart and Lung Research Institute
    Columbus OH. 43210
    View Details

  • Investigate the Development and Progression of Lung Disease in Rheumatoid Arthritis Over Time

    National Jewish Health
    Denver CO. 80206
    View Details

  • Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease

    University of Colorado - Anschutz Medical Campus
    Aurora CO. 80045
    View Details

  • Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients

    University of Washington
    Seattle WA. 98195
    View Details